Royal Bank of Canada’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $359K | Buy |
13,974
+6,439
| +85% | +$132K | ﹤0.01% | 4608 |
|
|
2026
Q1 | $145K | Sell |
7,535
-3,800
| -34% | -$75.6K | ﹤0.01% | 4911 |
|
|
2025
Q4 | $187K | Sell |
11,335
-360,841
| -97% | -$6.09M | ﹤0.01% | 4814 |
|
|
2025
Q3 | $5.4M | Sell |
372,176
-17,979
| -5% | -$258K | ﹤0.01% | 2610 |
|
|
2025
Q2 | $5.46M | Buy |
390,155
+375,719
| +2,603% | +$5.29M | ﹤0.01% | 2499 |
|
|
2025
Q1 | $196K | Sell |
14,436
-3,075
| -18% | -$58.9K | ﹤0.01% | 4714 |
|
|
2024
Q4 | $357K | Sell |
17,511
-4,420
| -20% | -$113K | ﹤0.01% | 4346 |
|
|
2024
Q3 | $639K | Buy |
21,931
+6,652
| +44% | +$165K | ﹤0.01% | 3899 |
|
|
2024
Q2 | $354K | Buy |
15,279
+8,220
| +116% | +$158K | ﹤0.01% | 4286 |
|
|
2024
Q1 | $146K | Sell |
7,059
-31,782
| -82% | -$597K | ﹤0.01% | 4943 |
|
|
2023
Q4 | $834K | Buy |
38,841
+20,867
| +116% | +$413K | ﹤0.01% | 3799 |
|
|
2023
Q3 | $371K | Buy |
17,974
+7,458
| +71% | +$189K | ﹤0.01% | 4281 |
|
|
2023
Q2 | $310K | Buy |
10,516
+1,429
| +16% | +$40.2K | ﹤0.01% | 4356 |
|
|
2023
Q1 | $209K | Sell |
9,087
-10,134
| -53% | -$279K | ﹤0.01% | 4588 |
|
|
2022
Q4 | $535K | Buy |
19,221
+15,206
| +379% | +$452K | ﹤0.01% | 4057 |
|
|
2022
Q3 | $123K | Sell |
4,015
-9,392
| -70% | -$305K | ﹤0.01% | 5175 |
|
|
2022
Q2 | $394K | Buy |
13,407
+5,026
| +60% | +$132K | ﹤0.01% | 4276 |
|
|
2022
Q1 | $269K | Sell |
8,381
-862
| -9% | -$29.7K | ﹤0.01% | 4823 |
|
|
2021
Q4 | $412K | Buy |
9,243
+5,175
| +127% | +$245K | ﹤0.01% | 4646 |
|
|
2021
Q3 | $205K | Sell |
4,068
-7,296
| -64% | -$411K | ﹤0.01% | 5145 |
|
|
2021
Q2 | $892K | Sell |
11,364
-24,617
| -68% | -$1.52M | ﹤0.01% | 3757 |
|
|
2021
Q1 | $2.06M | Buy |
35,981
+12,040
| +50% | +$806K | ﹤0.01% | 2977 |
|
|
2020
Q4 | $2M | Buy |
23,941
+22,341
| +1,396% | +$1.35M | ﹤0.01% | 2913 |
|
|
2020
Q3 | $57K | Buy |
1,600
+310
| +24% | +$9.34K | ﹤0.01% | 5284 |
|
|
2020
Q2 | $31K | Sell |
1,290
-153
| -11% | -$3.6K | ﹤0.01% | 5414 |
|
|
2020
Q1 | $25K | Sell |
1,443
-3,905
| -73% | -$81.5K | ﹤0.01% | 5445 |
|
|
2019
Q4 | $93K | Buy |
5,348
+4,948
| +1,237% | +$82.4K | ﹤0.01% | 5122 |
|
|
2019
Q3 | $6K | Hold |
400
| – | – | ﹤0.01% | 5944 |
|
|
2019
Q2 | $8K | Sell |
400
-7
| -2% | -$157 | ﹤0.01% | 6097 |
|
|
2019
Q1 | $9K | Sell |
407
-379
| -48% | -$7.93K | ﹤0.01% | 6032 |
|
|
2018
Q4 | $16K | Sell |
786
-742
| -49% | -$13.5K | ﹤0.01% | 5674 |
|
|
2018
Q3 | $34K | Buy |
1,528
+1,485
| +3,453% | +$24.6K | ﹤0.01% | 5416 |
|
|
2018
Q2 | $1K | Sell |
43
-25
| -37% | -$471 | ﹤0.01% | 6342 |
|
|
2018
Q1 | $1K | Sell |
68
-932
| -93% | -$19.2K | ﹤0.01% | 6190 |
|
|
2017
Q4 | $16K | Buy |
+1,000
| New | +$18K | ﹤0.01% | 5685 |
|
Other funds holding DNLI
Royal Bank of Canada's DNLI Position: Q2 2026 in Review
Royal Bank of Canada increased its Denali Therapeutics (DNLI) stake by 85% in Q2 2026, buying an estimated $132K and bringing the position to 13,974 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #4608.
Royal Bank of Canada first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.46M in Q2 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Royal Bank of Canada held 13,974 shares of Denali Therapeutics worth $359K as of Q2 2026.
- Royal Bank of Canada bought 6,439 Denali Therapeutics shares in Q2 2026, an estimated $132K.
- Denali Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4608 holding.
- Royal Bank of Canada first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Royal Bank of Canada's Denali Therapeutics position peaked at $5.46M in Q2 2025.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.